What are the recommended treatment options for primary premature ejaculation in men?

Treatment of Premature Ejaculation

For primary (lifelong) premature ejaculation, start with pharmacotherapy as first-line treatment using either dapoxetine 30-60 mg on-demand or lidocaine/prilocaine topical spray, combined with patient education and counseling. 1

Initial Assessment

Before initiating treatment, establish the diagnosis through:

• Medical and sexual history focusing on self-estimated intravaginal ejaculatory latency time (IELT), perceived control, distress level, and relationship impact 1
• Physical examination to identify anatomical abnormalities or coexisting erectile dysfunction 1
• No routine laboratory testing unless specific findings warrant investigation 1

Treatment Algorithm

First-Line Pharmacotherapy (Recommended for Lifelong PE)

Approved Options:

1. Dapoxetine (30-60 mg on-demand)

   • Increases IELT by 2.5-3.0 fold at standard doses
   • In men with baseline IELT <30 seconds: 3.4-4.3 fold improvement 1
   • Dose-dependent side effects: nausea, diarrhea, dizziness
   • Can be safely combined with PDE5 inhibitors 1
   • Caveat: High discontinuation rates (90% at 2 years) due to cost and disappointment with on-demand nature 1

2. Lidocaine/Prilocaine Spray (150 mg/50 mg)

   • Increases IELT up to 6.3-fold over 3 months 1
   • EMA-approved formulation
   • Minor side effects: genital hypoesthesia 1
   • Particularly effective for primary PE 2

Combination Therapy

For insufficient response to monotherapy: Combine dapoxetine with lidocaine/prilocaine spray 1, 2

Off-Label Options (Second-Line)

When approved treatments fail:

• Daily SSRIs (preferably paroxetine) for chronic use 1, 2
• Tramadol on-demand: Shows up to 2.5-fold IELT increase but use cautiously due to addiction potential and limited long-term safety data 1

Adjunctive Treatments

PDE5 Inhibitors:

• Do not significantly improve IELT alone
• Enhance confidence and sexual satisfaction 1
• Superior results when combined with SSRIs versus SSRI monotherapy 1

Critical Management Considerations

If Erectile Dysfunction Coexists

Treat ED first or concomitantly before addressing PE, as ED may be the primary driver 1, 2

Psychotherapy Integration

Always provide patient counseling and education about treatment options 1. The AUA/SMSNA guidelines emphasize shared decision-making and involving sexual partners when possible 3. While evidence for behavioral therapies alone is limited compared to pharmacotherapy 4, combining pharmacological and cognitive-behavioral approaches is recommended 2.

What NOT to Do

• Do not use α-1 blockers for PE treatment 2
• Do not recommend routine circumcision or frenulum surgery for PE 2
• Avoid surgical interventions and neuromodulation due to safety concerns and lack of guideline support 5

Evidence Quality Note

The 2025 EAU guidelines 1 represent the most current and comprehensive recommendations, with strong ratings for diagnostic approaches and pharmacotherapy as first-line treatment. All pharmacotherapy options in the US remain off-label as no FDA-approved PE medications exist 3, though dapoxetine and lidocaine/prilocaine spray have regulatory approval in other jurisdictions 1.